News

Luc7, the blue group of proteins, against a background of human cells.

Splice of life

MIT News

The Burge lab has discovered a new type of control over RNA splicing, a process critical for gene expression. Appearing in a new Nature Communications paper, their study sheds light on how this control mechanism can go wrong—and serve as a potential therapeutic target—in acute myelogenous leukemias and other diseases.

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

An enhanced view of gene transcription

MIT News

Regulating when genes are expressed, enhancers are promising drug targets for genetic disorders—when researchers can find them. Enhancers can reside far from the genes they regulate and leave only tiny amounts of eDNA, short-lived clues to their activation. Sharp Lab researchers led by postdoc D.B. Jay Mahat invented a technique, described in Nature, to facilitate eDNA isolation and observe coordination of gene expression and enhancer activation.

This work was supported in part by the Emerald Foundation.

Kinase atlas complete

MIT News

In a new Nature paper, the Yaffe Lab and collaborators map tyrosine kinase enzymes to their targets. This study, partly supported by the Charles and Marjorie Holloway Foundation and the L. Scott Ritterbush fund, builds on recent work mapping the other major kinase families to form a complete kinase atlas. This tool will enable researchers to map cell signaling pathways with unprecedented speed and detail, uncovering new biological insights and therapeutic targets for cancer.
 

Brio trio

MIT News

Of MIT’s 11 Fulbright winners this year, three hail from KI labs. Anusha Puri (Weinberg) is headed to the Swiss Institute for Experimental Cancer Research in Lausanne; Charvi Sharma (Yaffe) will teach English in Spain before resuming her clinician-scientist career path; and Isabella Witham (Belcher) is off to Seoul National University’s Biomimetic Materials and Stem Cell Engineering Lab.
The U.S. Department of State’s Fulbright U.S. Student Program offers one-year opportunities for overseas research, graduate study, or English language teaching to American students and recent alums.  

RNAi: An MIT case study

MIT News

Coinciding with the 50th anniversary of cancer research at MIT, a feature story tracing Alnylam’s success in developing RNAi therapies perfectly encapsulates the transformational impact and disciplinary diversity that characterize our community.  Incorporating contributions from the Sharp and Langer Labs, with their alumni and colleagues, Alnylam has several medicines approved by the FDA and a rapidly expanding clinical pipeline.

Engineering flexibility

MIT News

Combining microbiology, bioengineering, artificial intelligence, big data, and materials science, Belcher Lab graduate student Ashutosh Kumar’s research is a microcosm of the Koch Institute’s interdisciplinary model. Classically trained as an engineer working on steel design, Kumar is studying how the microbiome of ovarian cancer affects metastasis and treatment response.  His ultimate goal is to engineer bacteriophage viruses to reprogram bacteria to work therapeutically. Bacteriophage are a mainstay of the Belcher Lab’s signature research platforms, and being developed in a number of other ways for early detection and treatment as part of a larger ovarian cancer initiative led by Belcher, along with Sangeeta Bhatia and Paula Hammond.

Documenting innovation

MIT News

A new documentary, “Pathways to Invention,” follows a diverse group of modern inventors—all of whom are Lemelson-MIT Student Prize recipients, including KI alum Geoff von Maltzahn '03, PhD '10—as they develop life-changing innovations. The program airs this summer on PBS stations nationwide, including WGBH 44 Boston on July 19.  

Al Masri wins Soros Fellowship for New Americans

MIT News

Congratulations to Riyam Al Msari, a graduate student in the Irvine and Wittrup labs, on receiving a 2024 Paul and Daisy Soros Fellowship for New Americans. Al Msari arrived in the US following a childhood in Iraq shaped by war, and a transformative experience serving as primary caretaker during her mother’s battle with head and neck cancer, which inspired her work to pioneer translational cancer therapies.

It’s a hard day’s night for the liver

MIT News

Just like in our bodies, circadian rhythms in our cells and genes regulate critical processes such as immune activity and metabolism.

In a Science Advances study, the Bhatia lab developed tiny, engineered human livers, and found that many genes involved in drug metabolism are under circadian control. Because these rhythms affect how much of a drug is available to the body and how effectively it breaks it down, they could be analyzed to improve dosing schedules for drugs, including chemotherapies.

It’s the same old thing, since 1916

MIT News

Based on one equation developed in 1916 using data from nine patients, chemotherapy dosing calculations do not account for several variables that can lead to toxicity or insufficient benefit in patients.

Described in Med and funded in part by the Bridge Project, the Traverso and Langer Labs developed CLAUDIA, a closed-loop drug delivery system designed to tailor doses of chemotherapy to individual patients for maximum safety and effectiveness.

Microfluidic device reveals leukemia cell behaviors in the blood

MIT Koch Institute

Scott Manalis and Michael Hemann published a new study in Communications Biology that improves our basic understanding of circulating leukemia cell dynamics over the course of disease progression and therapeutic response.

Understanding these circulation kinetics and clearance rates can inform our biological understandings of metastasis, as well as the design of tools that target these circulating cells for cancer diagnosis, treatment and monitoring.